Rituximab in New Onset Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

November 30, 2009

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Anti-CD20 (rituximab)

DRUG

Placebo Comparator

Placebo intravenous infusion

Trial Locations (16)

10032

Columbia University, New York

15213

University of Pittsburgh, Pittsburgh

33136

University of Miami, Miami

46202

Indiana University-Riley Hospital for Children, Indianapolis

55455

University of Minnesota, Minneapolis

80010

Barbara Davis Center for Childhood Diabetes, Aurora

90027

Childrens Hospital of Los Angeles, Los Angeles

94143

University of California-San Francisco, San Francisco

94305

Stanford University, Stanford

98101

Benaroya Research Institute, Seattle

32610-0296

University of Florida, Gainesville

02215

Joslin, Boston

75235-8858

University of Texas, Dallas

Unknown

Walter and Eliza Hall Institute of Medical Research, Victoria

San Raffaele Hospital, Milan

M5G 1X8

The Hospital for Sick Children, Toronto

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

American Diabetes Association

OTHER

collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH